Journal
NPJ VACCINES
Volume 7, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41541-022-00535-4
Keywords
-
Categories
Funding
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Disease [R01 NIDDK093094]
- National Institute of Allergies and Infectious Diseases [R01 AI151013]
- National Cancer Institute [U54 CA221204, R35 CA197463]
- National Cancer Institute, National Institutes of Health [75N91019D00024/HHSN261201500003I]
Ask authors/readers for more resources
This article summarizes the epidemiology and biology of Kaposi sarcoma herpesvirus (KSHV) as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.
Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the low-hanging fruit that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop's findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
